Information on the implemented tax strategy for 2023
Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
Code of conduct
This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Press Release PB UW 25.08.2020
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.
Polpharma’s innovative child is ready to harvest
Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs.
Building an integrated biosimilars business
Polpharma Biologics is a fast-growing business that develops and manufactures
biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also
delivers biopharmaceutical CDMO services.
Press release 03.09.2019
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.
Metabolic control of CHOBC® for production of biologics
Process optimisation for biologics is obligatory for efficient processing and reduction
of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to
manufacture the antibody provides a competitive advantage compared to competing biosimilar
developers.